Video

Andrew J. Cutler, MD: The Impact of Screen Time on ADHD

Author(s):

A large portion of communication is non-verbal.

While screening and diagnostic techniques for attention deficit/ hyperactivity disorder (ADHD) have not changed much in recent decades, the growing reliance on new technology may be making it more challenging.

In an interview with HCPLive®, Andrew J. Cutler, MD, Clinical Professor of Psychiatry at SUNY Upstate Medical University, explained how more screen time for all adolescents is making the diagnostic process for ADHD more challenging.

Cutler explained that the time adolescents and adults spend using cell phones and tablets has increased in recent years, making it more difficult for some doctors to diagnose the disorder because a large portion of conversations are non-verbal.

“Something very significant is lost in our ability to pick up verbal cues—facial expressions, mannerisms,” Cutler said. “In general, it has made it harder to make the diagnosis.”

However, it could be helpful for some patients more comfortable with virtual technology and less comfortable with one-on-one interactions.

Cutler also said with more people working from home and students doing virtual schooling, screen time might begin to drastically increase. He also said there is some concerns with less in-person therapy sessions that patients will forgo their treatments more commonly and fill less prescriptions.

At the annual Neuroscience Education Institute Max! Virtual meeting, Cutler will present multiple times about ADHD and other psychiatric disorders.

Related Videos
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Wei Zhang, MD, PhD: Naltrexone’s GI, Liver Safety for Alcohol Use Disorder Treatment
Jeffrey Teckman, MD | Credit: AASLD
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban| Image Credit: Brigham & Women's Hospital
Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage | Image Credit: Mayo Clinicn HFpEF
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Minjee Kim, MD: Understanding Sleep’s Impact on Post-Liver Transplant Outcomes
© 2024 MJH Life Sciences

All rights reserved.